Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
CA 2455227 C · Owner: Ensoli, Barbara · Inventors: Ensoli, Barbara
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS other infectious , diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof as a , module with one or more of the following features: antigen adjuvant and , targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular it is , claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens to prime or to boost , protective immune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 26, 2002 and granted January 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 26, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 26, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.